Envoy Medical logo

Envoy MedicalNASDAQ: COCH

Profile

Sector:

Healthcare

Country:

United States

IPO:

29 April 2021

Next earnings report:

15 November 2024

Last dividends:

N/A

Next dividends:

N/A
$44.69 M
-77%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-123%vs. 3y high
7%vs. sector
147.98
-76%vs. 3y high
95%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:59:46 GMT
$2.28-$0.36(-13.63%)

Dividend

No data over the past 3 years
$68.00 K$80.00 K
$68.00 K-$3.95 M

Analysts recommendations

Institutional Ownership

COCH Latest News

Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
globenewswire.com01 November 2024 Sentiment: POSITIVE

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients

Envoy Medical to Present at the LD Micro Main Event XVII
globenewswire.com23 October 2024 Sentiment: POSITIVE

WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Envoy Medical Awarded Patent for Recharge System used with Implantable Battery
globenewswire.com16 September 2024 Sentiment: POSITIVE

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss

Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update
globenewswire.com12 August 2024 Sentiment: POSITIVE

Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year

Envoy Medical Announces Inclusion in the Russell Microcap Index
globenewswire.com01 July 2024 Sentiment: POSITIVE

WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares for inclusion in its Microcap Index. The inclusion became effective at the close of market on Friday, June 28, 2024.

Envoy Medical Announces Inclusion in the MSCI USA Micro Cap Index
globenewswire.com06 June 2024 Sentiment: POSITIVE

WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index.  The inclusion became effective at the close of market on Friday, May 31, 2024.  The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024.  A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.

Envoy Medical Is Pursuing Filling A Hearing Industry Void
seekingalpha.com19 May 2024 Sentiment: POSITIVE

Envoy Medical is a company that provides fully implantable hearing devices for individuals with moderate to severe hearing loss. Their second device, Acclaim, has received Breakthrough Device designation and is set to start clinical trials for FDA approval. Envoy's devices have benefits including no need for external devices, no cleaning necessary, no risk of expensive replacements, and continuous usage around the clock.

Envoy Medical, Inc. to Present at The Microcap Conference
Newsfile Corp30 January 2024 Sentiment: POSITIVE

White Bear Lake, Minnesota--(Newsfile Corp. - January 30, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing systems, will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ. Brent Lucas, Chief Executive Officer, will be presenting on January 31 & February 1, 2024.

What type of business is Envoy Medical?

Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

What sector is Envoy Medical in?

Envoy Medical is in the Healthcare sector

What industry is Envoy Medical in?

Envoy Medical is in the Medical Devices industry

What country is Envoy Medical from?

Envoy Medical is headquartered in United States

When did Envoy Medical go public?

Envoy Medical initial public offering (IPO) was on 29 April 2021

What is Envoy Medical website?

https://www.envoymedical.com

Is Envoy Medical in the S&P 500?

No, Envoy Medical is not included in the S&P 500 index

Is Envoy Medical in the NASDAQ 100?

No, Envoy Medical is not included in the NASDAQ 100 index

Is Envoy Medical in the Dow Jones?

No, Envoy Medical is not included in the Dow Jones index

When was Envoy Medical the previous earnings report?

No data

When does Envoy Medical earnings report?

The next expected earnings date for Envoy Medical is 15 November 2024